FAS Wealth Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.22M | Buy |
32,676
+2,047
| +7% | +$440K | 0.43% | 53 |
|
|
2026
Q1 | $6.66M | Buy |
30,629
+1,064
| +4% | +$236K | 0.41% | 58 |
|
|
2025
Q4 | $6.76M | Buy |
29,565
+1,315
| +5% | +$300K | 0.44% | 55 |
|
|
2025
Q3 | $6.54M | Buy |
28,250
+524
| +2% | +$107K | 0.44% | 52 |
|
|
2025
Q2 | $5.15M | Buy |
27,726
+1,375
| +5% | +$256K | 0.38% | 56 |
|
|
2025
Q1 | $5.52M | Buy |
26,351
+1,064
| +4% | +$207K | 0.45% | 51 |
|
|
2024
Q4 | $4.49M | Buy |
25,287
+499
| +2% | +$91.7K | 0.38% | 63 |
|
|
2024
Q3 | $4.9M | Buy |
24,788
+808
| +3% | +$151K | 0.39% | 60 |
|
|
2024
Q2 | $4.11M | Buy |
23,980
+945
| +4% | +$157K | 0.36% | 63 |
|
|
2024
Q1 | $4.19M | Buy |
23,035
+582
| +3% | +$100K | 0.37% | 62 |
|
|
2023
Q4 | $3.48M | Buy |
22,453
+625
| +3% | +$91.1K | 0.33% | 66 |
|
|
2023
Q3 | $3.25M | Buy |
21,828
+555
| +3% | +$81.5K | 0.35% | 62 |
|
|
2023
Q2 | $2.87M | Buy |
21,273
+1,015
| +5% | +$149K | 0.36% | 67 |
|
|
2023
Q1 | $3.23M | Sell |
20,258
-1,988
| -9% | -$304K | 0.35% | 57 |
|
|
2022
Q4 | $3.6M | Buy |
22,246
+1,886
| +9% | +$289K | 0.41% | 56 |
|
|
2022
Q3 | $2.73M | Buy |
20,360
+2,792
| +16% | +$401K | 0.3% | 55 |
|
|
2022
Q2 | $2.69M | Buy |
17,568
+2,422
| +16% | +$370K | 0.28% | 59 |
|
|
2022
Q1 | $2.46M | Buy |
15,146
+1,638
| +12% | +$238K | 0.23% | 67 |
|
|
2021
Q4 | $1.83M | Buy |
13,508
+2,085
| +18% | +$246K | 0.17% | 86 |
|
|
2021
Q3 | $1.23M | Buy |
11,423
+425
| +4% | +$48.6K | 0.12% | 111 |
|
|
2021
Q2 | $1.24M | Buy |
10,998
+1,174
| +12% | +$132K | 0.12% | 111 |
|
|
2021
Q1 | $1.06M | Buy |
9,824
+1,117
| +13% | +$119K | 0.11% | 115 |
|
|
2020
Q4 | $933K | Buy |
8,707
+1,200
| +16% | +$115K | 0.11% | 120 |
|
|
2020
Q3 | $658K | Buy |
7,507
+443
| +6% | +$41.7K | 0.09% | 139 |
|
|
2020
Q2 | $694K | Buy |
7,064
+1,098
| +18% | +$96.7K | 0.1% | 129 |
|
|
2020
Q1 | $455K | Buy |
5,966
+2,995
| +101% | +$255K | 0.08% | 138 |
|
|
2019
Q4 | $263K | Buy |
+2,971
| New | +$247K | 0.04% | 174 |
|
|
2019
Q2 | – | Sell |
-2,844
| Closed | -$229K | – | 192 |
|
|
2019
Q1 | $229K | Sell |
2,844
-138
| -5% | -$11.3K | 0.04% | 178 |
|
|
2018
Q4 | $275K | Sell |
2,982
-151
| -5% | -$13.3K | 0.06% | 164 |
|
|
2018
Q3 | $296K | Buy |
3,133
+8
| +0.3% | +$759 | 0.07% | 153 |
|
|
2018
Q2 | $290K | Buy |
3,125
+7
| +0.2% | +$684 | 0.08% | 148 |
|
|
2018
Q1 | $295K | Sell |
3,118
-186
| -6% | -$20.4K | 0.09% | 142 |
|
|
2017
Q4 | $319K | Sell |
3,304
-87
| -3% | -$8.2K | 0.08% | 141 |
|
|
2017
Q3 | $301K | Buy |
3,391
+60
| +2% | +$4.57K | 0.08% | 138 |
|
|
2017
Q2 | $242K | Buy |
+3,331
| New | +$224K | 0.07% | 147 |
|
Other funds holding ABBV
FAS Wealth Partners's ABBV Position: Q2 2026 in Review
FAS Wealth Partners increased its AbbVie (ABBV) stake by 6.7% in Q2 2026, buying an estimated $440K and bringing the position to 32,676 shares worth $8.22M. The position accounts for 0.43% of the portfolio, ranked #53.
FAS Wealth Partners first reported a position in ABBV in Q2 2017 and has held it in 35 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- FAS Wealth Partners held 32,676 shares of AbbVie worth $8.22M as of Q2 2026.
- FAS Wealth Partners bought 2,047 AbbVie shares in Q2 2026, an estimated $440K.
- AbbVie made up 0.43% of FAS Wealth Partners's portfolio in Q2 2026, its #53 holding.
- FAS Wealth Partners first reported a position in AbbVie in Q2 2017 and has held it in 35 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on FAS Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.